Prostate Cancer | Clinical

FDA Updates Prescribing Information for Darolutamide in nmCRPC

January 08, 2021

The FDA has updated the Prescribing Information for the approved agent darolutamide to include improvement in overall survival in patients with non-metastatic castration-resistant prostate cancer, as well as other secondary end point data, from the phase 3 ARAMIS clinical trial.

Deciding on an Agent for Prostate Cancer Involves Careful Consideration of Prior Therapy

December 28, 2020

Anthony A. Meluch, MD, medical oncologist, Tennessee Oncology, discussed treatment options for high-risk adenocarcinoma of the prostate based on the case of a 75-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.